Literature DB >> 15446553

[Pathological evaluation of soft tissue sarcoma for diagnosis, prognosis and treatment].

Umio Yamaguchi1, Tadashi Hasegawa.   

Abstract

Soft tissue sarcomas (STS) are rare and heterogeneous group of tumors which differ widely in their clinicopathological features, and have a wide spectrum of clinical course, ranging from indolent tumors with a good prognosis to highly aggressive tumors with a poor prognosis. The diagnostic process of STS is complex and may necessitate an array of ancillary studies, including immunohistochemistry, electron microscopy and molecular genetic methods. Although an ongoing and improved histopathological definition of individual tumor types has been established, there still remains a subset of mesenchymal tumors which are currently not readily classifiable. This review summarizes our experience and that of others in the approach to the pathological evaluation of STS, and especially emphasizes the need to use emerging molecular techniques that can provide important clues for diagnosis, prognosis, and treatment of STS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15446553

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region.

Authors:  Antoine Lurkin; Francoise Ducimetière; Dominique Ranchère Vince; Anne-Valérie Decouvelaere; Dominic Cellier; François N Gilly; Dimitri Salameire; Pierre Biron; Guy de Laroche; Jean Yves Blay; Isabelle Ray-Coquard
Journal:  BMC Cancer       Date:  2010-04-19       Impact factor: 4.430

2.  MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities -- an analysis of 140 patients.

Authors:  Marcus Lehnhardt; Adrien Daigeler; Heinz H Homann; Vanessa Schwaiberger; Ole Goertz; Cornelius Kuhnen; Hans U Steinau
Journal:  Langenbecks Arch Surg       Date:  2008-06-27       Impact factor: 3.445

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.